

L'analyse pharmaceutique est-elle en train de vivre une révolution?

Davy GUILLARME




Remerciements: *Prof. Jean-luc Veuthey, Prof. Serge Rudaz
et autres collègues de notre laboratoire*

Analysis in the pharmaceutical industry

- Pharmaceutical industry is one of the most regulated production worldwide, since the drug products have to be **safe and effective**.
- The levels of synthesis impurities and degradation products in active pharmaceutical ingredients (API) have to be **strictly controlled** and should meet the specifications required by international authorities.
- **Chromatography** has been the technique of choice for many years to assess chemical purity of drug substances and products, and is widely used in the pharmaceutical industry from research and development to quality control (QC) laboratories.



LC-UV impurity profiling





1. The quest for performance (speed / resolution)

UHPLC: use of columns packed with sub-2 μm particles + systems with extended upper pressure limit (1000-1500 bar)



High Throughput

$N \approx 10'000$ plates
 $t_{\text{ana}} < 2 \text{ min}$ ($k=10$)



$N \approx \text{cst}$




$T_r \div 9$




High Resolution

$N \approx 90'000$ plates
 $t_{\text{ana}} < 20 \text{ min}$ ($k=10$)




$N \times 9$



$T_r \approx \text{cst}$


Fast, very fast and ultra-fast LC analysis...

Fast analysis




D. Cheng, J. Chromatogr. Sci., 53 (2015) 1280

Very fast analysis 2012



Ultra fast analysis

Colonnes de 1 cm, 3 mm, 1.9 μm @ 8 mL/min



D.W. Armstrong et al., Anal. Chem. 90 (2018) 3349


FUTURE TRENDS:

- Spectroscopy (RAMAN, near IR...)
- Sensors
- ...

> 2020


High resolution LC-UV analysis

Analysis of a solution containing the four APIs present in stribild oral tablet (elvitegravir, emtricitabine, cobicistat and tenofovir) for VIH treatment, with their spiked respective impurities.



High resolution LC-MS analysis



Analysis of a standardized extract of *Ginkgo Biloba*



FUTURE TRENDS: 2D-LC

2. The quest for selectivity

Pharmaceutical products are more and more complex today
(i.e. API with 3 chiral centers)



**Modeling
software**

Tuning selectivity

SFC

Alternative selectivity


2D-LC

Improve selectivity


**MS
IM-MS**

Selective detector

LC optimization software




- ☐ Drylab
- ☐ Chromsword
- ☐ ACD/LC simulator
- ☐ Osiris



T=50 C, t_G =9 min, pH=5.76

OPTIMIZATION
(12 experiments + modeling)




- Elution window stretching
- Multilinear gradient

ROBUSTNESS
(calculation based on modeling,
simulation of 729 – 17496 experiments)


- Simulated
full factorial design**
- Gradient program
 - pH
 - Temperature
 - Flow-rate

REFINEMENT
(calculation based on modeling
+ 1 verification experiment)




- Adjustment of column length
- Gradient program scaling

Simulated chromatogram



Experimental chromatogram





Supercritical fluid chromatography (SFC)

Supercritical state is a hybrid state of matter that can be reached by increasing both temperature and pressure above the critical point.

- ❑ Supercritical fluid viscosity is equivalent to that of a gas
- ❑ Supercritical fluid density is equivalent to that of a liquid




Stationary phase: polar
Mobile phase: mostly CO_2 (apolar) mixed with MeOH (polar)




The power of 2D-LC

LCxLC-UV


Comprehensive enantioselective 2D-LC



RPLCxSFC-UV




RPLCxHILIC of peptides




RPLCxRPLC-UV/MS


(a) 2D-Contour plots




(b) 2D separation (TIC chromatogram)



(c) Extraction of MS Spectra





Ion mobility - mass spectrometry (IM-MS)




- Compatibility with LC and MS
- High orthogonality with LC
- Highly stable IMS drift times
- Limited peak capacity of IMS
- Expensive/difficult instruments

Plasma proteome



m/z=316



3. The quest for sensitivity

Genotoxic impurities (ex. nitrosamines) can be found in drug substances and pharmaceutical products.

General impurities should be present at 500 ppm maximum (0.05% level), but genotoxic impurities should be at **1 ppm maximum** (ultra-trace level !).



Cleaning validation is required to establish the cleanliness of manufacturing equipment.

A limit of **10 ppm** of the previously manufactured product is allowed to appear in subsequent products.

In **bioanalysis**, there is a need to achieve very low level of detection (**1 – 10 ppb**) in body fluids.

This is particularly true in therapeutic drug monitoring (**TDM**) and pharmacokinetics (**PK**).



MS as a solution to tackle sensitivity issue?

LC-MS market

Compact single quadrupole MS



Genotoxic impurities,
cleaning validation

MS/MS instruments



Quantitative
bioanalysis

High resolution MS



Untargeted analysis
(-omics)

4. The quest for miniaturization (On-site LC)



Bronze pittcon excellence award in 2018




Developed in the laboratories of Prof. Milton Lee at Brigham Young University, the Axcend Focus LC opens up new opportunities for analysis as the world's **first truly mobile gradient liquid chromatograph**.



- Internal battery - portable
- Visual output to any web-connected smartphone/tablet
- High sensitivity with LED UV-detector
- 1 week of use only produces a spoon of waste


Commercial portable LC system

Application notes with Axcend Focus LC system




ANALYSIS OF 12 CANNABINOIDS STANDARD

Due to its small size, low-weight, hand-portability, and lower solvent usage, the Axcend Focus LC is uniquely suited for field and laboratory analysis of cannabinoid compounds. As shown below, we also detected and identified 12 separate cannabinoids in a Restek standard.



5 PROTEIN TEST COMPOUNDS



Probably unsuitable for complex analytical problems

Biopharmaceuticals: A new challenge in pharmaceutical analysis ?



Pharmaceutical market in 2004

→ In 2004, only **1** drug among the **TOP 10** can be considered as biopharmaceuticals.



		Market 2004 Sales (\$ billion)	Active ingredient	Small molecule/ Biologics	Indication(s)
1	Sortis	12	Atorvastatine	Small molecule	Hypercholesterolemia
2	Zocor	5.9	Simvastatine	Small molecule	Hypercholesterolemia
3	Plavix	5	Clopidogrel	Small molecule	Thrombosis
4	Nexium	4.8	Esomeprazole	Small molecule	Ulcer
5	Zyprexa	4.8	Olanzapine	Small molecule	Neuroleptic
6	Norvasc	4.8	Amlodipine	Small molecule	Hypertension
7	Seretide	4.7	Salmeterol	Small molecule	Bronchodilator
8	Erypo	4	Alpha-Epoetin	Protein	Anemia
9	Ogastro	3.8	Lansoprazole	Small molecule	Ulcer
10	Effexor	3.7	Venlafaxine	Small molecule	Antidepressive

Pharmaceutical market in 2017

→ In 2017, **7** drugs among the **TOP 10** can be considered as biopharmaceutics (mAbs, fusion proteins).



		Market 2017 Sales (\$ billion)	Active ingredient	Small molecule/ Biologics	Indication(s)
1	Humira	18.4	Adalimumab	Monoclonal Antibody	Rheumatoid arthritis
2	Rituxan	9.2	Rituximab	Monoclonal Antibody	Various cancers
3	Revlimid	8.1	Lenalidomide	Small molecule	Various cancers
4	Enbrel	7.8	Etanercept	Fusion protein	Rheumatoid arthritis
5	Herceptin	7.4	Trastuzumab	Monoclonal Antibody	Breast cancers
6	Eliquis	7.3	Apixaban	Small molecule	Anticoagulant
7	Remicade	7.1	Infliximab	Monoclonal Antibody	Rheumatoid arthritis
8	Avastin	7.0	Bevacizumab	Monoclonal Antibody	Various cancers
9	Xarelto	6.5	Rivaroxaban	Small molecule	Anticoagulant
10	Eylea	6.0	Aflibercept	Fusion protein	Macular degeneration


Analytical characterization of molecules

Small molecules




salicylic acid
MW 138 Da

Peptides




triptorelin
MW 1,311 Da

Proteins




human growth hormone
MW 22,125 Da

mAbs



Rituximab
MW ~150,000 Da

ADC



Brenduximab-vedotin
MW ~150,000 Da

Analytical complexity




Important micro-heterogeneity during the production of biologics



Analytical challenge !

Evolution of analytical toolbox for proteins




Electrophoresis

1990's



Chromatography

2000's



LC-MS and 2D-LC

2010's

Primary
sequence

AA analysis
MALDI-TOF

AA analysis
LC-ESI-MS/MS

AA analysis
UHPLC-**ESI-HRMS**
2D-LC-**ESI-MS**

Size
variants

SEC
SDS-PAGE

SEC
CGE

UHP-SEC (**MS**)
CGE
A4F

Charge
variants

IEF
IEX

cIEF
IEX

icIEF
CZE
Modern IEX (**MS**)

Glycan
analysis

CZE-LIF (APTS)

CZE-LIF (APTS)
HILIC-FD (2-AB)

CE-LIF (**MS**) (APTS)
HILIC-MS (Rapidfluor)
MALDI-**TOF/MS**

High order
structure

Calorimetry
(DSC)

CD
Fluorescence


HDX-MS
Near and far-UV CD
NMR

RPLC of intact proteins – possible?


For a long time, proteins were only analyzed in RPLC at the peptide level. Thanks to the numerous technological progresses, RPLC can now also be used at the intact protein level.

What are the challenges associated with RPLC of proteins?

Limited kinetic performance




Poor recovery





Ion pairing dependence

Reliance on high temperature







- Core-shell particles
- Sub-2 μm particles
- Large pore-size
- Temperature stability
- Optimized chemistry



Modern SEC: using sub-3 μm columns



Mobile phase: 100 mM disodium hydrogen-phosphate buffer and 200 mM sodium chloride in water, pH 6.8 at 25°C and columns were operated at 350 $\mu\text{L}/\text{min}$




Modern SEC columns: faster analysis, good chemical inertness

pH-gradient IEX: an alternative for mAbs?



Generic pH-gradient method for the characterisation of 10 intact mAbs



- Column: YMC BioPro SP-F (100 x 4.6 mm).
- Mobile phase: "A" Thermo CX-1 buffer **pH=5.6**, "B" Thermo CX-1 buffer **pH=10.2**
- Gradient: 0 – 100 %B in 20 min
- Flow rate: 0.6 mL/min
- Temperature: 30 °C
- Detection: FL (280 – 360 nm)



Similar performance in salt and pH gradient.

No need to manually prepare buffers, interesting solution for the industry.

Conclu

From an an

- Speed
- Select
- Sens
- Minia

Increasing c

- Mixtu
- API w
- Diffic
- low d
- Bioph
- Oligo

Main bottler

- Data
- Regu

Possible alt

- Spec

- Speed / Resolution
- Selectivity
- Sensitivity
- Miniaturization/simplification



- Mixture of several API (i.e. HIV treatment)
- API with multiple chiral centers
- Difficult formulation (surfactants, lipids, cyclodextrins...) to address low drug solubility
- Biopharmaceuticals + biosimilars + new mAb formats
- Oligonucleotides, cell and gene therapy



- Data treatment
- Regulatory aspects are more and more strict



- Spectroscopy (RAMAN, NIR)

